UPPSALA, SWEDEN – LIDDS AB (publ) today announces that its most recent family of patents on the NanoZolid® production process, and therefore on the resulting pharmaceutical products, have been granted in China. The patent offers protection until 2037 in this market.
“We are delighted to see that our delivery technology has received IP validation in another important market,” said Nina Herne, CEO of LIDDS.
Recently, LIDDS received patent approval in China (Patent No. 2017800630120). The invention covering the process and products based on NanoZolid® the technology provides protection until 2037. In addition, the patent protects all pharmaceutical products obtained with the process described in the patent. In 2021, the same patent family also received approvals in Russia, Australia, India, South Africa and Singapore. The patent and a related divisional patent are already approved in the United States, as previously communicated.
For more information please contact:
Nina Herne, CEO, +46 (0)70 714 7457, email: [email protected] Inasmuch as
The information was submitted for publication, via the aforementioned contact person, on December 17 at 09:30 CET.
LIDDS AB (publ) is a Sweden-based pharmaceutical company focused on a unique proprietary drug delivery technology: NanoZolid®. NanoZolid® is a clinically validated drug development technology superior in its ability to provide controlled and sustained release of active drug substances for up to six months. LIDDS has licensing agreements where NanoZolid® is combined with anti-androgens and in-house clinical and pre-clinical development projects for cytostatics and immunoactive agents. LIDDS shares are listed on the Nasdaq First North Growth Market (LIDDS ticker). Redeye AB is the LIDDS certified advisor (+46 (0) 8 121 576 90, email: [email protected]) For more information, please visit www.liddspharma.com.